Announcements

Announcements
 
 
Paul G. Allen Frontiers Group    [to 2 May 2020]
https://alleninstitute.org/what-we-do/frontiers-group/news-press/
News
Scientists are working on a face mask that detects coronavirus
April 23, 2020
Q&A with James Collins, Ph.D., a bioengineer who is developing a diagnostic face mask that signals if the wearer is infected with COVID-19
 
 
BMGF – Gates Foundation  [to 2 May 2020]
http://www.gatesfoundation.org/Media-Center/Press-Releases
Website under maintenance at inquiry.
 
 
Bill & Melinda Gates Medical Research Institute    [to 2 May 2020]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
InVivo Profiles Bill & Melinda Gates Medical Research Institute
 
 
CARB-X   [to 2 May 2020]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.
 
 
CEPI – Coalition for Epidemic Preparedness Innovations  [to 2 May 2020]
http://cepi.net/
Latest News
CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals’ Australian Subsidiary
27 Apr 2020
CEPI establishes Representative Office in Shanghai, China
27 Apr 20
 
 
Clinton Health Access Initiative, Inc. (CHAI)  [to 2 May 2020]
https://clintonhealthaccess.org/
News & Press Releases
April 28, 2020
Unitaid and CHAI announce agreement with Omega Diagnostics to increase access to new, portable CD4 testing device for people living with HIV in over 130 low- and middle-income countries
Agreement with Omega Diagnostics will help deliver same-day CD4 testing for people living with HIV in over 130 low- and middle-income countries at just US$3.98 per test.
 
 
EDCTP    [to 2 May 2020]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.
 
 
Emory Vaccine Center    [to 2 May 2020]
http://www.vaccines.emory.edu/
[Undated]
EVC RESONDS TO COVID-19
EVC COVID-19 RESEARCH UPDATE
 
 
European Medicines Agency  [to 2 May 2020]
http://www.ema.europa.eu/ema/
News & Press Releases ·
Press release: EMA starts rolling review of remdesivir for COVID-19
Last updated: 30/04/2020
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020
CHMP, Last updated: 30/04/2020
Press release: EU actions to support availability of medicines during COVID-19 pandemic – update #4
Last updated: 30/04/2020
News: International regulators pledge collective support to combat COVID-19 pandemic
Last updated: 28/04/2020
 
 
European Vaccine Initiative  [to 2 May 2020]
http://www.euvaccine.eu/news-events
Latest News
No new digest content identified.
 
 
FDA [to 2 May 2020]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements
May 1, 2020 – Coronavirus (COVID-19) Update: Daily Roundup May 1, 2020
The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:
   :: Today, the FDA issued an Emergency Use Authorization (EUA) for the investigational antiviral drug remdesivir. The EUAExternal Link Disclaimer allows for remdesivir to be distributed in the :: U.S. and administered by health care providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. Severe disease is defined as patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support such as a mechanical ventilator. Based on evaluation of the emergency use authorization criteria and the scientific evidence available, it was determined that it is reasonable to believe that remdesivir may be effective in treating COVID-19, and that, given there are no adequate, approved, or available alternative treatments, the known and potential benefits to treat this serious or life-threatening virus currently outweigh the known and potential risks of the drug’s use. For more information see: news release, Health Care Provider Fact Sheet and Patient Fact Sheet.

  :: Today, the FDA updated its guidance on convalescent plasma and associated web page. The updated guidance provides clarification for investigators on how to submit investigational applications for COVID-19 convalescent plasma. In addition, the guidance includes updated information regarding potential donors. Previously, the FDA’s guidance noted that to qualify, individuals should have complete resolution of symptoms for 28 days or resolution for 14 and a negative diagnostic test. The revised guidance recommends that individuals  have complete resolution of symptoms for at least 14 days prior to donation A negative lab test for COVID-19 disease is not necessary to qualify for donation. The revised guidance also clarifies that FDA does not recommend storing a retention sample from the convalescent plasma donation for single patient emergency INDs…
 
 
May 1, 2020 – Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
Today, the U.S. Food and Drug Administration issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. While there is limited information known about the safety and effectiveness of using remdesivir to treat people in the hospital with COVID-19, the investigational drug was shown in a clinical trial to shorten the time to recovery in some patients.

“FDA’s emergency authorization of remdesivir, two days after the National Institutes of Health’s clinical trial showed promising results, is a significant step forward in battling COVID-19 and another example of the Trump Administration moving as quickly as possible to use science to save lives,” said HHS Secretary Alex Azar. “NIH, FDA, and scientists across America and around the world have worked tirelessly with patients to get us this new potential treatment for COVID-19. The seamless cooperation between government and private industry under the President’s all-of-America approach to COVID-19 is getting treatment options to patients in record time.”

The emergency use authorization allows for remdesivir to be distributed in the U.S. and administered intravenously by health care providers, as appropriate, to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. Severe disease is defined as patients with low blood oxygen levels or needing oxygen therapy or more intensive breathing support such as a mechanical ventilator…
 
 
Fondation Merieux  [to 2 May 2020]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.
 
 
Gavi [to 2 May 2020]
https://www.gavi.org/
Top Stories
1 May 2020
28 April 2020: Overview of the COVID-19 situation in Gavi-supported countries and Gavi’s response
 
 
1 May 2020
Keeping routine immunisation going during COVID-19 in Indonesia
 
 
30 April 2020
World Immunization Week: Eradicating cervical cancer through HPV vaccination
 
 
GHIT Fund   [to 2 May 2020]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.
 
 
Global Fund  [to 2 May 2020]
https://www.theglobalfund.org/en/news/
Updates
Ethics Resources for Country Coordinating Mechanisms
30 April 2020
Ethical, transparent and responsible decision-making by Country Coordinating Mechanisms is key for the success of programs in countries – and advancing the fight against HIV, tuberculosis and malaria worldwide.
To support Country Coordinating Mechanisms in following the highest standards of ethics and integrity, the Global Fund has published new resources:
Translations of the Code of Ethical Conduct for Country Coordinating Mechanism Members
:: An e-learning course introducing the Code of Ethical Conduct
:: Guidelines for ethics focal points and ethics committees
To access these resources and for more information, see the Country Coordinating Mechanism Ethics page.
 
 
Hilleman Laboratories   [to 2 May 2020]
http://www.hillemanlabs.org/
No new digest content identified.
 
 
Human Vaccines Project   [to 2 May 2020]
http://www.humanvaccinesproject.org/media/press-releases/
Press Releases
Global COVID Lab Meeting Will Bring Together the Worldwide Scientific Community to Accelerate Development of Vaccines and Immunotherapies
Apr 30, 2020
New York City (April 23, 2020). The Global COVID Lab Meeting will connect the worldwide scientific community working to develop vaccines and immunotherapies to end the COVID-19 pandemic. The Human Vaccines Project is starting this bi-weekly webinar to feature leading scientists from across the globe presenting their latest data, with ample time allowed for questions and discussion.
 
 
“The engines of science are the weekly or bi-weekly lab meetings held across the globe by individual laboratory directors, enabling faculty, post-docs and graduate students to present their latest findings and catalyze new ideas,” says Wayne C. Koff, president and CEO of the Human Vaccines Project. “The urgency of the pandemic, coupled with technological advances of distance learning, now enables us to bring the global scientific community together to accelerate the development of vaccines and immunotherapies for prevention and control of COVID-19. The Global COVID Lab Meeting will provide researchers with a neutral forum to share their findings and innovative ideas with scientists from across the world on a regular basis, thereby increasing the probability for identifying solutions towards ending the COVID-19 pandemic.”
 
 
The webinar will be held every first and third Thursday of the month at 10 am EST. The first session is on May 7th. Dr. James E. Crowe Jr., Director of the Vanderbilt Vaccine Center, will talk about his studies on identification and development of human monoclonal antibodies for SARS-CoV-2 – a treatment that could provide immediate immunity to first responders. Dr. Crowe’s lab is one of the leading groups globally working on antibody identification and is targeting starting clinical studies early this summer for SARS-CoV-2 therapeutics. You can register for the webinar here.
 
 
IAVI  [to 2 May 2020]
https://www.iavi.org/newsroom
Press Releases
No new digest content identified.
 
 
International Coalition of Medicines Regulatory Authorities [ICMRA]
http://www.icmra.info/drupal/en/news
Selected Statements, Press Releases, Research
No new digest content identified.
 
 
International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.
 
 
IFFIm
http://www.iffim.org/
Press Releases
No new digest content identified.
 
 
IFRC   [to 2 May 2020]
http://media.ifrc.org/ifrc/news/press-releases/
Selected Press Releases, Announcements
No new digest content identified.
 
 
IVAC  [to 2 May 2020]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates
Vaccination Services Must Continue Even as We Fight COVID-19
April 2020
By Dr. Chizoba Wonodi, Immunization Technical Lead, USAID’s MOMENTUM 2A: Global Technical Leadership and Targeted Technical Assistance
Nigeria, like all other countries in the world, is grappling with the devasting public health, social, and economic fallouts of the COVID-19 pandemic. As of April 27, 2020, Nigeria has 1273 confirmed cases, a dramatic increase since February […]
 
 
IVI   [to 2 May 2020]
http://www.ivi.int/
Selected IVI News & Announcements
INOVIO and GeneOne Life Science Report Positive Phase 1/2a Clinical Data With DNA Vaccine INO-4700 for MERS Coronavirus at the American Society of Gene & Cell Therapy (ASGCT) Conference
:: INO-4700 (GLS-5300) DNA vaccine demonstrates 100% binding and 92% neutralizing antibody responses against MERS-CoV
:: INO-4800 DNA vaccine for COVID-19 currently in Phase 1 trial utilizes identical strategy targeting Spike protein and CELLECTRA intradermal delivery
April 28, 2020
 
 
JEE Alliance  [to 2 May 2020]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.
 
 
MSF/Médecins Sans Frontières  [to 2 May 2020]
http://www.msf.org/
Latest [Selected Announcements]
Vaccination
Overcoming barriers so vaccines can save lives
Project Update 29 Apr 2020
 
 
Coronavirus COVID-19 pandemic
Overwhelming, lonely, stressful – life in a COVID-19 unit in Geneva
Voices from the Field 27 Apr 2020
 
 
National Vaccine Program Office – U.S. HHS  [to 2 May 2020]
https://www.hhs.gov/vaccines/about/index.html
NVAC 2020 Meetings
June 9-10, 2020 NVAC Meeting
September 23-24, 2020 Meeting (Virtual)
 
 
NIH  [to 2 May 2020]
http://www.nih.gov/news-events/news-releases
Selected News Releases
NIH clinical trial shows Remdesivir accelerates recovery from advanced COVID-19
April 29, 2020 — Preliminary results indicate that patients who received remdesivir had a 31% faster time to recovery than those who received placebo.
 
 
NIH mobilizes national innovation initiative for COVID-19 diagnostics
April 29, 2020 — Initiative aims to speed delivery of accurate, easy-to-use, scalable tests to all Americans.
 
 
PATH  [to 2 May 2020]
https://www.path.org/media-center/
Selected Announcements
April 24, 2020
PATH establishes Representative Office in Shanghai, China
Registration will enable PATH to implement health projects directly with partners
 
 
PATH partners with Ukraine to develop a national response to COVID-19
Seattle, WA, April 24, 2020 – PATH is partnering with the Ukraine government to develop and implement a comprehensive national response to COVID-19. PATH’S country office program will use the expertise acquired from leading infectious disease surveillance, pandemic flue emergency preparedness, and tuberculosis control in Ukraine since 1994 to address four important areas of the national response…
 
 
Sabin Vaccine Institute  [to 2 May 2020]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
No new digest content identified.
 
 
UNAIDS [to 2 May 2020]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
1 May 2020
Paying tribute to care workers during an online Labour Day event

1 May 2020
“The concern did not just come from the community, but also the health workers”

29 April 2020
“We must ensure that HIV treatment adherence is not compromised”—keeping people in Pakistan on HIV treatment

28 April 2020
“I’ve saved lives on the frontline of the COVID-19 pandemic in China”

28 April 2020
Women are more likely to be on HIV treatment
 
 
UNICEF  [to 2 May 2020]
https://www.unicef.org/media/press-releases
Press release
Geneva Palais briefing note on the impact of COVID-19 mitigation measures on vaccine supply and logistics
01/05/2020
[See COVID-19 above for detail]

Statement
COVID-19 & Immigration Detention: What Can Governments and Other Stakeholders Do?
Statement by the United Nations Network on Migration
29/04/2020

Press release
Over 5 million children face threat of cholera and acute water diarrhea in the midst of COVID-19 as Yemen gets heavy rains
29/04/2020

Press release
Disruption of childhood vaccination in South Asia poses an urgent threat to children’s health – UNICEF
4.5 million of South Asia’s children miss out on routine immunization, even before COVID-19
28/04/2020
[See COVID-19 above for detail]

Press release
COVID-19: Gavi and UNICEF to secure equipment and diagnostics for lower-income countries
28/04/2020
 
 
Unitaid  [to 2 May 2020]
https://unitaid.org/
Featured News
27 April 2020
Unitaid congratulates Ellen ‘t Hoen on national honour recognising her efforts on access and equity
Geneva — Unitaid congratulates Ellen ‘t Hoen on the announcement that H.M. King Alexander of the Netherlands has conferred on her the title of ‘Officier in de Orde van Oranje-Nassau’, in recognition of her important contribution on global health and access to medicines at the international level.
Amongst her many achievements, Ellen ‘t Hoen was instrumental in setting up the Medicines Patent Pool ten years ago in 2010, which Unitaid has funded since its creation. She also was its first Executive Director…
 
 
Vaccination Acceptance Research Network (VARN)  [to 2 May 2020]
https://vaccineacceptance.org/news.html#header1-2r
Announcements
No new digest content identified.
 
 
Vaccine Confidence Project  [to 2 May 2020]
http://www.vaccineconfidence.org/
Latest News & Archive
No new digest content identified.
 
 
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 2 May 2020]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.
 
 
Wellcome Trust  [to 2 May 2020]
https://wellcome.ac.uk/news
Opinion | 29 April 2020
COVID-19: how researchers around the world are racing to understand the virus and prevent future outbreaks
by Josie Golding

News | 27 April 2020
The future of vaccines: three innovations from around the world
World Immunisation Week is an opportunity to celebrate some of the most cutting-edge vaccination projects and technologies from around the world, which have the potential to improve health for millions of people.
 
 
The Wistar Institute   [to 2 May 2020]
https://www.wistar.org/news/press-releases
Press Releases
Press Release  May. 1, 2020
The Wistar Institute Appoints Bin Tian, Ph.D., 
as Professor in the Cancer Center and 
Co-director of the Center for Systems & Computational Biology
PHILADELPHIA — (May, 1, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of molecular systems biologist Bin Tian, Ph.D., as professor in the Cancer Center.

Press Release  Apr. 30, 2020
The Wistar Institute Appoints Virology Expert Italo Tempera, Ph.D., as Associate Professor in Its Cancer Center
PHILADELPHIA — (April 30, 2020) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of Italo Tempera, Ph.D., as associate professor in the Gene Expression & Regulation Program of The Wistar Institute Cancer Center.

Press Release   Apr. 29, 2020
The Wistar Institute and Batavia Biosciences Launch Collaboration to Manufacture and Distribute Wistar’s Rubella Vaccine Globally
The Bill & Melinda Gates Foundation supports international collaboration to expand global access to life-saving vaccines
 
 
WFPHA: World Federation of Public Health Associations  [to 2 May 2020]
https://www.wfpha.org/
Latest News
Open Letter to The United Nations: Call for The Establishment of a Multi-sector “Global Health Equity Task Force” to Confront The Impact of COVID-19 Pandemic
Monday, 27 April 2020
Global Health Inquity is a fact. The present crisis renders visible these inequities. The World Federation of Public Health Associations (WFPHA) has signed an open letter to the United Nations proposing that the UN Secretary General provide the necessary support to the World Health Organization (WHO), by creating a multi-sector “Global Health Equity Task Force” to confront the impact of the COVID-19 pandemic in its full health, socio-demographic and economic dimensions.

As the unique international non-governmental body representing the interests of the global public health community through national and regional public health associations and associated organizations, WFPHA is concerned about the impact of the COVID-19 pandemic among already vulnerable and marginalized populations worldwide. Disadvantaged and marginalized populations are more at risk to become infected. When infected, marginalized people are more likely to evolve to severe cases as they suffer disproportionately higher rates of chronic diseases, obesity and malnutrition.

The “Global Health Equity Task Force”, housed within WHO, would be charged with taking the necessary steps to exert needed global leadership for a comprehensive, equity-focused response to the pandemic, guided by the ethical principles of justice, beneficence and nonmaleficence and the Universal Declaration of Human Rights. It would encourage international cooperation towards fair allocation of resources to all countries according to need.

Full Letter with List of Institutions is Available Here.

List of Individual Signing the Letter is Available Here.
 
 
World Organisation for Animal Health (OIE)   [to 2 May 2020]
https://www.oie.int/en/for-the-media/press-releases/2020/
Press Releases
No new digest content identified.

::::::

 
 
ARM [Alliance for Regenerative Medicine]  [to 2 May 2020]
https://alliancerm.org/press-releases/
Press Releases
No new digest content identified.
 
 
BIO    [to 2 May 2020]
https://www.bio.org/press-releases
Press Releases
No new digest content identified.
 
 
DCVMN – Developing Country Vaccine Manufacturers Network  [to 2 May 2020]
http://www.dcvmn.org/
News
DCVMN joined Global leaders call for a new collaboration to accelerate equitable access to Covid-19 Health technologies

Geneva, 24th April 2020 – The COVID-19 pandemic requires a strong united front to turn the tide of this global public health burden. Recognizing the April 20th United Nations General Assembly resolution [1], calling for rapid development, scale-up, manufacturing and supply of vaccines to confront the pandemic, the Developing Countries Vaccine Manufacturers Network (DCVMN) stands ready to fully collaborate with the Access to COVID Tools (ACT) Accelerator initiative, launched on 24th April 2020…
 
 
IFPMA   [to 2 May 2020]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
Global Pharma update on unprecedented efforts to collaborate in speeding up the search for safe
30 April 2020
 
 
PhRMA    [to 2 May 2020]
http://www.phrma.org/
Selected Press Releases, Statements
The continued imperative to protect U.S. innovation worldwide
Chris Moore   |     April 29, 2020
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are collaborating with others and working around the clock to research and develop vaccines and treatments to beat the virus.
The 2020 Special 301 Report released today by the Office of the United States Trade Representative (USTR) highlights just how essential open markets and effective intellectual property protections and enforcement are to meeting today’s challenges and to delivering tomorrow’s new treatments and cures. The report confirms the U.S. government’s strong commitment to defend and promote fair market access for American inventions, including biopharmaceuticals, in countries around the world.

Thanks to its domestic intellectual property and market-based policy environment, the United States leads the world in the research and development of new medicines. With the right policies in place, the new treatments and cures pioneered here can continue to benefit patients everywhere. There are notable examples from the 2020 Special 301 Report of how USTR is defending American innovators:

:: Ensuring transparency and fairness of pharmaceutical pricing and reimbursement policies in Canada, Japan and South Korea so trading partners appropriately recognize the value of innovative medicines and contribute their fair share to research and development of new treatments and cures.

:: Combating the negative impact of compulsory licensing actions in Asia, the Middle East, Latin America and other regions.

:: Condemning weak intellectual property protection and other policies in Argentina, India, Malaysia, and enhancing engagement with Saudi Arabia by conducting an out-of-cycle review to resolve longstanding concerns…

Guest Post: Preserving clinical research sites during the coronavirus pandemic

April 29, 2020

Jim Kremidas, executive director of the Association of Clinical Research Professionals